Results of lebrikizumab in moderate-to-severe atopic dermatitis from two phase 3 trials
In this medfyle
In the induction period of ADvocate 1 and ADvocate 2 trials, a 16-week treatment with 250 mg lebrikizumab was effective in adolescents and adults with moderate-to-severe atopic dermatitis. Lebrikizumab improved itch scores, and in particular reduced itch interference with patients’ sleep, while it showed an overall good safety profile with mild or moderate adverse events.
About this Medfyle
©2024 Medfyle. All rights reserved.
Original article:
Silverberg JI, Guttman-Yassky E, Thaçi D, Irvine AD, Stein Gold L, Blauvelt A, Simpson EL, Chu CY, Liu Z, Gontijo Lima R, Pillai SG, Seneschal J; ADvocate1 and ADvocate2 Investigators. Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. N Engl J Med. 2023 Mar 23;388(12):1080-1091. doi: 10.1056/NEJMoa2206714. Epub 2023 Mar 15. PMID: 36920778.
The summary content was prepared by Marta Castano for Medfyle, and reviewed by Martina Lambertini, MD.
The authors of the original article and the publisher were not involved in the creation of the summary.
